{
    "ticker": "AGIO",
    "name": "Agios Pharmaceuticals, Inc.",
    "description": "Agios Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the lives of patients with genetically defined diseases through the discovery, development, and commercialization of innovative therapies. Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios focuses on metabolic pathways to treat rare genetic diseases and cancer. The company's pioneering approach leverages its deep understanding of cellular metabolism to develop targeted therapies, including products for conditions such as acute myeloid leukemia (AML) and pyruvate kinase deficiency (PK deficiency). Agios is committed to advancing precision medicine by utilizing genetic insights to enhance the effectiveness of treatments while minimizing side effects. With a robust pipeline, the company continues to explore new therapeutic avenues, aiming to address unmet medical needs in hematologic malignancies and inherited metabolic disorders. Agios collaborates with various partners to accelerate drug development and expand its reach in the biopharmaceutical landscape. The company\u2019s mission is to unlock the potential of metabolism to deliver transformative therapies for patients facing serious diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2008",
    "website": "https://www.agios.com",
    "ceo": "David P. Schenkein, M.D.",
    "social_media": {
        "twitter": "https://twitter.com/agiospharma",
        "linkedin": "https://www.linkedin.com/company/agios-pharmaceuticals"
    },
    "investor_relations": "https://investors.agios.com",
    "key_executives": [
        {
            "name": "David P. Schenkein, M.D.",
            "position": "CEO"
        },
        {
            "name": "Andrew Hirsch",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "TIBSOVO (ivosidenib)",
                "IDHIFA (enasidenib)"
            ]
        },
        {
            "category": "Rare Genetic Diseases",
            "products": [
                "AG-348"
            ]
        }
    ],
    "seo": {
        "meta_title": "Agios Pharmaceuticals, Inc. | Transformative Therapies for Genetic Diseases",
        "meta_description": "Learn about Agios Pharmaceuticals, Inc., a leader in biopharmaceuticals focused on genetic diseases and cancer. Explore our innovative therapies and commitment to precision medicine.",
        "keywords": [
            "Agios",
            "Biopharmaceuticals",
            "Genetic Diseases",
            "Cancer Treatments",
            "Precision Medicine",
            "TIBSOVO",
            "IDHIFA"
        ]
    },
    "faq": [
        {
            "question": "What does Agios Pharmaceuticals focus on?",
            "answer": "Agios Pharmaceuticals focuses on developing therapies for genetically defined diseases and cancer through innovative metabolic approaches."
        },
        {
            "question": "Who is the CEO of Agios Pharmaceuticals?",
            "answer": "David P. Schenkein, M.D., is the CEO of Agios Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Agios Pharmaceuticals headquartered?",
            "answer": "Agios Pharmaceuticals is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are some key products of Agios?",
            "answer": "Key products include TIBSOVO (ivosidenib) for AML and IDHIFA (enasidenib), as well as AG-348 for PK deficiency."
        },
        {
            "question": "When was Agios Pharmaceuticals founded?",
            "answer": "Agios Pharmaceuticals was founded in 2008."
        }
    ],
    "competitors": [
        "EDIT",
        "SRPT",
        "CRSP",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}